BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bordeaux Institute of Oncology - ECPv6.17.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bordeaux Institute of Oncology
X-ORIGINAL-URL:https://www.bricbordeaux.com/en/
X-WR-CALDESC:Events for Bordeaux Institute of Oncology
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260127T140000
DTEND;TZID=Europe/Paris:20260127T150000
DTSTAMP:20260106T111830Z
CREATED:20260106T111830Z
LAST-MODIFIED:20260106T111830Z
UID:50730-1769522400-1769526000@www.bricbordeaux.com
SUMMARY:Invited Seminar Kevin Boyé
DESCRIPTION:We invite Kevin Boyé to give a seminar open to the scientific community. \nDr. Kevin Boyé\nCRCN INSERM Paris Cardiovascular Research Center – 56 Rue Leblanc\, 75015 Paris\nCo-founder of D2B3 – 101 College Street\, 06511 New Haven\, CT\, USA \n \n“Unlocking the Blood–Brain Barrier during Glioblastoma progression” \n📆 Tuesday\, January 27\, 2 p.m.\n🚩 BBS Conference Room\, 2 rue Dr Hoffmann Martinot\, Carreire site\, University of Bordeaux \nAbstract \nBlood vessels in the brain form 600 kilometers of specialized blood-brain barrier (BBB) that protect the brain from toxins and pathogens\, thereby ensuring homeostasis and proper neurological function. However\, BBB impermeability also severely limits brain drug delivery during many neurological disorders. \nGlioblastoma (GBM) is the most aggressive primary brain tumor with a median survival of 12–15 months. Although BBB integrity is partially disrupted within the tumor core\, the highly invasive nature of GBM cells into the BBB-competent brain parenchyma strongly limits the delivery and efficacy of therapeutic molecules\, leading to inevitable recurrence after surgical resection. Hence\, developing tailored therapeutic strategies that can transiently and safely modulate BBB permeability without compromising its protective function remains a major unmet clinical need. \nWe recently identified the endothelial receptor Unc5B and its ligand Netrin-1 as central regulators of BBB integrity. Single-cell RNA sequencing revealed that this pathway controls a core BBB gene expression program of over 100 genes involved in tight junction organization\, nutrient and ion transport\, and efflux pump function. To harness this mechanism therapeutically\, we developed\, optimized\, and patented a fully human monoclonal antibody (Anti-Unc5B) that specifically blocks Netrin-1 binding to Unc5B. \nFollowing intravenous injection\, Anti-Unc5B induces a brain-wide and brain-specific\, opening of the BBB for up to six hours\, prior to barrier resealing. This transient permeability window is size-selective\, cumulative and safe. Using this BBB-permeabilizing strategy\, we could enhance the delivery and efficacy of a wide variety of therapeutic molecules including chemotherapies\, tyrosine kinase inhibitors and nanobodies during GBM progression\, resulting in increased tumor cell apoptosis\, reduced tumor growth and improved survival. \nBiosketch \nI completed my PhD in the laboratory of Pr. Andreas Bikfalvi under the supervision of Dr. Clotilde Billottet (INSERM U1029\, France)\, where I identified the chemokine receptor CXCR3-A and its ligand CXCL4L1 as a novel signaling pathway essential for brain tumor progression (Boyé K. et al.\, Nature Communications 2017; Boyé K. et al.\, Scientific Reports 2017; Quemener C et al. Cancer Research 2016). However\, like most therapeutic molecules developed for neurological diseases\, intravenously injected CXCR3-A inhibitors were unlikely to efficiently cross the blood–brain barrier (BBB). \nTo overcome this limitation\, I joined the laboratory of Pr. Anne Eichmann at Yale University (New Haven\, USA) as a postdoctoral fellow (2017-2022)\, where I investigated mechanisms regulating vascular barrier integrity (Genet G.\, Boyé K. et al. Nature Communication 2019; Zhang F. et al. Science 2018)\, with a particular focus on the BBB (Boyé K. et al.\, Nature Communications 2022). I identified the endothelial Unc5B receptor and its ligand Netrin-1 as a key signaling pathway required to maintain BBB integrity. I subsequently developed a human monoclonal antibody that block Netrin-1 binding to Unc5B\, enabling a reversible and controlled BBB opening leading to brain delivery of bioactive molecules (Two Patents in 2023). \n  \nSince 2023\, I am a Group Leader (CRCN) at the Paris Cardiovascular Research Center (INSERM U970). My group is currently funded by an FRM “Amorçage jeunes équipes” (2023-2026)\, an ANR PRC (Coordinator; 2026 – 2028) and an INCa PLBIO (Coordinator; 2026 – 2028). My research program focuses on: \n\nOptimizing brain drug delivery beyond the BBB during brain tumor progression.\nEnhancing BBB integrity in diseases with BBB dysfunction.\n\nWe recently reported a BBB gene-expression program zonated along the arteriovenous axis that can be tuned to increased brain drug delivery (Furtado et al.\, PNAS 2024). \n  \nIn 2024 I co-founded D2B3 (https://d2b3.bio)\, a start-up company spun out of Yale University\, aiming to improve brain drug delivery in patients using our patented BBB-permeabilization technology.
URL:https://www.bricbordeaux.com/en/event/invited-seminar-kevin-boye/
LOCATION:Salle de conférence BBS (Bordeaux Biologie Santé)\, 2 rue Dr Hoffmann Martinot\, Bordeaux
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2026/01/invited-seminar-kevin-boye-27-01-2026.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260131
DTEND;VALUE=DATE:20260201
DTSTAMP:20260120T165008Z
CREATED:20250625T130142Z
LAST-MODIFIED:20260120T165008Z
UID:50850-1769817600-1769903999@www.bricbordeaux.com
SUMMARY:Digestive Cancer Open Day 2026
DESCRIPTION:2026 Open Day on Digestive Cancers on Saturday\, January 31\, 2026. \nBRIC is once again holding an Open Day at its premises in Bordeaux\, on the Carreire campus (BBS building). Find information on our website dedicated to the general public:  \n  \npatient website \n  \nThis initiative\, which is fully in line with the goal of scientific outreach\, aims to introduce the general public\, in a variety of formats\, to the daily lives of researchers and recent advances in the field of digestive cancer research. The programme includes : \n\n\nContinuous reception (except from 12:30 p.m. to 1:45 p.m.)\n\n\n\nSeminars on the Cancer Research/Care and Innovation Ecosystem in the Region (11 a.m. and 2 p.m.)\n\n\n\nInteractive guided tours of the laboratory\, including 3 workshops:\n\nWorkshop: “Discovering Living Cells”\n\n\n\nWorkshop: “The journey of a sample”: from biopsy to treatment\n\n\n\nEscape Game Workshop\n\n\n\n\n\nWorkshops on “Observation of tumor tissues” (ongoing)\n\n\n\nExchange activity: “Ask all your questions” (ongoing)\n\n\n\nGuided discoveries into the mechanisms of cancer\, drug development\, and various therapies. (ongoing)\n\n\n\nStand of the Gironde Cancer League (continuous)\n\n\n\nDiscovery of a biological model (ongoing)\n\n\nTours departing with workshop participation at 10 a.m.\, 11 a.m.\, 2 p.m.\, and 3 p.m. Other activities ongoing throughout the day. \n\nCome and discuss\, around posters or mini-seminars\, with various contributors involved in the research: – Academic research professionals (researchers and teacher-researchers\, engineers and technicians\, doctoral students and interns) – Clinical research professionals – Clinicians\, including surgeons and oncologists \n\nPatient associations\, including La Ligue Contre le Cancer de Gironde (the Gironde Cancer League) and a start-up company spun off from the laboratory\, will also be present! \n\nCome visit the laboratory and take the opportunity to put on a lab coat and gloves and participate in fun workshops! This project is led by teams 3\, 4\, and 8 at BRIC\, in collaboration with several supervisory bodies (Inserm\, University of Bordeaux) and scientific partners: (Bordeaux University Hospital\, OncoProt\, BeLiver\, Bergonié Institute). \n  \nAccess: \n🚘Apart from the parking spaces reserved for university staff (badge required)\, you will find spaces closer by on the sidewalk along the wall on Rue du Dr Hoffmann Martinot. Otherwise\, there is a parking lot reserved for visitors a 5-minute walk away\, located at 125 Bethmann Street. \n🚊Take tram A to the Saint Augustin stop\, then follow the “cycles et piétons” (cycles and pedestrians) markings on the ground across the CHU campus. \n🚍Several bus lines nearby\, see location map \n  \nlocation map
URL:https://www.bricbordeaux.com/en/event/digestive-cancer-open-day-2026/
LOCATION:Accueil bâtiment Bordeaux Biologie Santé (BBS)\, 2 rue Dr Hoffmann Martinot\, Bordeaux\, France
CATEGORIES:Meetings,Scientific seminars
ATTACH;FMTTYPE=image/jpeg:https://cdn-bricbordeaux.onlc.eu/wp-content/uploads/2025/06/vignette-jpo-cancers-digestifs-bric-31-01-2026.jpg
END:VEVENT
END:VCALENDAR